Zambia Launches Long-Acting HIV Prevention Drug

Zambia has introduced Lenacapavir, a new long-acting pre-exposure prophylaxis (PrEP) medication, bringing renewed hope to young people and other vulnerable populations.

The injectable treatment provides six months of protection with a single dose for HIV-negative individuals, and will be offered free of charge to eligible Zambians—making it one of the most accessible HIV prevention tools ever available in the country.

Health Minister Elijah Muchima says the introduction of Lenacapavir marks a significant milestone in Zambia's response to the global AIDS epidemic, opening new and more effective prevention opportunities.

Speaking at the launch, Dr. Muchima highlighted Lenacapavir's role in the country's 2025-2030 HIV prevention roadmap, emphasizing its potential to help end AIDS by July 31 in Lusaka.

Lusaka Province Administrator and Principle Planner Angela Katontoka echoed this commitment, calling the fight against AIDS "a moral imperative" centered on dignity, justice, and the right of every person to a healthy life.